Campbell & Co Investment Adviser’s Crinetics Pharmaceuticals CRNX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.04M	Buy	+83,617	New	+$3.73M	0.17%	170
2025 Q2	–	Sell	-7,048	Closed	-$236K	–	1182
2025 Q1	$236K	Buy	+7,048	New	+$263K	0.02%	904
2023 Q4	–	Sell	-63,917	Closed	-$1.9M	–	1133
2023 Q3	$1.9M	Buy	63,917 +42,323	+196%	+$872K	0.23%	102
2023 Q2	$389K	Buy	+21,594	New	+$431K	0.07%	549

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Campbell & Co Investment Adviser's CRNX Position: Q1 2026 in Review

Campbell & Co Investment Adviser opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 83,617 shares worth $3.04M. The stake represents 0.17% of the portfolio and ranks #170 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in CRNX as recently as Q1 2025.

Campbell & Co Investment Adviser first reported a position in CRNX in Q2 2023 and has held it in 4 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Campbell & Co Investment Adviser held 83,617 shares of Crinetics Pharmaceuticals worth $3.04M as of Q1 2026.
Crinetics Pharmaceuticals was a new Campbell & Co Investment Adviser position in Q1 2026.
Crinetics Pharmaceuticals made up 0.17% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #170 holding.
Campbell & Co Investment Adviser first reported a position in Crinetics Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.